Navigation Links
Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
Date:2/25/2008

FRANKFURT, Germany, February 25 /PRNewswire/ -- t2cure, a clinical stage biopharmaceutical company developing novel regenerative therapies based on autologous progenitor cells, announced today that it has appointed Dr. Petra Rueck Head of Clinical Operations.

"We are pleased to have Petra join our company", said Manfred Ruediger, CEO of t2cure. "Petra's experience in clinical research and project management will be of critical importance to t2cure as we are preparing to move our lead product into Phase III clinical trials for severe infarcts."

"It is a unique opportunity to contribute to the development of therapies that have the potential to significantly improve patient outcomes", said Petra Rueck. "t2cure's clinical candidates have demonstrated their capacity to increase the regenerative potential of tissue damaged by acute myocardial infarctions and other cardiac or peripheral vascular diseases."

Prior to joining t2cure, Dr Rueck was a project leader with ratiopharm's Biogenerix AG, Mannheim, where most recently she was responsible for a biotechnology project including the design and management of preclinical and clinical development programs. Her previous experience includes positions in clinical research management at Pfizer and Intervet. Before that, Dr. Rueck was assistant professor at Berlin University Hospital "Benjamin Franklin" (now Charite) and worked as postdoctoral researcher at INSERM, Paris. Petra Rueck received her PhD degree in pharmacology from the University of Giessen, Germany, where she studied veterinary medicine.

About t2cure GmbH

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy). The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development and will enter Phase III soon. t2cure is privately financed with Entrepreneurs Fund BV, Amsterdam as lead investor.

Contact:

Manfred Ruediger, CEO

t2cure GmbH

Bettinastrasse 35-37

D-60325 Frankfurt am Main

Tel: +49-69-75-61-46-87-0

Fax: +49-69-75-61-46-87-9

Email: infot2cure.com

http://www.t2cure.com


'/>"/>
SOURCE t2cure GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
2. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
3. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
4. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
5. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
6. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
7. LS9, Inc., the Renewable Petroleum Company(TM), Adds Key Positions to Executive Team and Scientific Advisory Board
8. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
10. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
11. Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):